Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hyperlipidemias

ClinicalTrials.gov lists 2,329 trials for Hyperlipidemias or a narrower condition beneath it. Organon and Co has the most among industry and government lead sponsors, with 93.

MeSH D006949 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 240 Phase 1/2 Phase 1/2 33 Phase 2 Phase 2 268 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 451 Phase 4 Phase 4 243 Not applicable Not applicable 697 Observational Observational 350 Phase 1 Phase 1 240 Phase 1/2 Phase 1/2 33 Phase 2 Phase 2 268 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 451 Phase 4 Phase 4 243 Not applicable Not applicable 697 Observational Observational 350

Trials per phase (log scale)

2 more sections with rows

842 of the 2,329 trials are tagged with Hyperlipidemias itself; the rest are tagged with a narrower condition beneath it.

Get the Hyperlipidemias report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hyperlipidemias trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 117

1990: 4 trials (Observational 3, Phase 2 1) 1991: 4 trials (Observational 3, Phase 3 1) 1992: 7 trials (Observational 3, Phase 3 2, Phase 2 1, Phase 1 1) 1993: 3 trials (Observational 1, Phase 3 1, Phase 1 1) 1994: 2 trials (Observational 1, Phase 4 1) 1996: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 1997: 2 trials (Not applicable 1, Phase 1 1) 1998: 6 trials (Observational 2, Not applicable 1, Phase 2 3) 1999: 10 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 2) 2000: 21 trials (Observational 3, Not applicable 3, Phase 3 9, Phase 2 5, Phase 1 1) 2001: 16 trials (Observational 3, Not applicable 2, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 3) 2002: 41 trials (Observational 3, Not applicable 8, Phase 4 7, Phase 3 15, Phase 2/3 1, Phase 2 5, Phase 1 2) 2003: 64 trials (Observational 9, Not applicable 6, Phase 4 16, Phase 3 22, Phase 2/3 1, Phase 2 8, Phase 1/2 1, Phase 1 1) 2004: 66 trials (Observational 11, Not applicable 11, Phase 4 10, Phase 3 21, Phase 2 6, Phase 1/2 2, Phase 1 5) 2005: 99 trials (Observational 8, Not applicable 14, Phase 4 25, Phase 3 40, Phase 2/3 1, Phase 2 9, Phase 1/2 2) 2006: 79 trials (Observational 9, Not applicable 18, Phase 4 10, Phase 3 21, Phase 2/3 2, Phase 2 14, Phase 1/2 2, Phase 1 3) 2007: 109 trials (Observational 15, Not applicable 26, Phase 4 14, Phase 3 26, Phase 2/3 3, Phase 2 14, Phase 1/2 1, Phase 1 10) 2008: 84 trials (Observational 7, Not applicable 26, Phase 4 16, Phase 3 14, Phase 2/3 1, Phase 2 14, Phase 1/2 2, Phase 1 4) 2009: 87 trials (Observational 17, Not applicable 20, Phase 4 19, Phase 3 11, Phase 2/3 3, Phase 2 4, Phase 1/2 5, Phase 1 8) 2010: 86 trials (Observational 20, Not applicable 21, Phase 4 14, Phase 3 9, Phase 2/3 3, Phase 2 7, Phase 1/2 2, Phase 1 10) 2011: 110 trials (Observational 5, Not applicable 22, Phase 4 16, Phase 3 19, Phase 2/3 3, Phase 2 20, Phase 1 25) 2012: 113 trials (Observational 11, Not applicable 40, Phase 4 8, Phase 3 17, Phase 2/3 7, Phase 2 15, Phase 1/2 1, Phase 1 14) 2013: 101 trials (Observational 13, Not applicable 32, Phase 4 5, Phase 3 28, Phase 2 12, Phase 1 11) 2014: 93 trials (Observational 19, Not applicable 26, Phase 4 6, Phase 3 17, Phase 2 8, Phase 1/2 2, Phase 1 15) 2015: 86 trials (Observational 12, Not applicable 28, Phase 4 7, Phase 3 16, Phase 2/3 1, Phase 2 10, Phase 1 12) 2016: 110 trials (Observational 16, Not applicable 36, Phase 4 10, Phase 3 21, Phase 2/3 3, Phase 2 11, Phase 1/2 1, Phase 1 12) 2017: 82 trials (Other 1, Observational 16, Not applicable 20, Phase 4 11, Phase 3 13, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 7) 2018: 82 trials (Observational 10, Not applicable 34, Phase 4 10, Phase 3 9, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 11) 2019: 74 trials (Observational 9, Not applicable 34, Phase 4 5, Phase 3 8, Phase 2/3 4, Phase 2 7, Phase 1/2 2, Phase 1 5) 2020: 77 trials (Observational 16, Not applicable 28, Phase 4 4, Phase 3 11, Phase 2 10, Phase 1 8) 2021: 81 trials (Observational 11, Not applicable 30, Phase 4 4, Phase 3 20, Phase 2 10, Phase 1 6) 2022: 91 trials (Observational 20, Not applicable 35, Phase 4 2, Phase 3 13, Phase 2 8, Phase 1 13) 2023: 87 trials (Observational 13, Not applicable 41, Phase 4 3, Phase 3 14, Phase 2 6, Phase 1/2 1, Phase 1 9) 2024: 117 trials (Observational 24, Not applicable 52, Phase 4 3, Phase 3 13, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 14) 2025: 89 trials (Observational 9, Not applicable 43, Phase 4 4, Phase 3 8, Phase 2 10, Phase 1/2 3, Phase 1 12)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 95
2025 89
2024 117
2023 87
2022 91
2021 81
2020 77
2019 74
2018 82
2017 82

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 100 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 32 months from start to primary completion across 146 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 1,611 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hyperlipidemias trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 240
Phase 1/2 33
Phase 2 268
Phase 2/3 40
Phase 3 451
Phase 4 243
Not applicable 697
Observational 350
Expanded access 6
Unknown 1

How many Hyperlipidemias trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 66
Recruiting 145
Enrolling by invitation 19
Active, not recruiting 59
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hyperlipidemias trials? (14)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Organon and Co 93
AstraZeneca 89
Amgen 42
National Heart, Lung, and Blood Institute (NHLBI) 41
Novartis Pharmaceuticals 41

Showing 5 of 14 sponsors.

Start your 14-day trial Email me all 14 sponsors as a PDF

Which drugs are being tested for Hyperlipidemias? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 168
Ezetimibe 111
ROSUVASTATIN 106
SIMVASTATIN 68
Evolocumab 54

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 36
Inclisiran (Leqvio®) 300mg 30
pitavastatin Ca 2mg 26
Pravastatin Pill 24
Statin 18

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hyperlipidemias trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,735 84
Angina unstable 1,580 81
Angina pectoris 1,528 87
Osteoarthritis 1,237 60
Number with All Cause Hospitalization in 12 months 1,136 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hyperlipidemias? (935)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Digital solution for salutogenic brain health: a pilot sequential multiple assignment randomised trial (SMART) protocol for clinical implementation. BMJ open 2025 Yes
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study. Journal of the American College of Cardiology 2025 Yes
Effect of sleep restriction, with or without prior evening exercise, on morning postprandial lipemia. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2025 Yes
Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. Nature medicine 2025 Yes
Enhancing Comorbidity Management in Patients With Hemorrhagic Stroke via an Electronic Health Record-Linked Best Practice Alert: A Pre/Post Study. Journal of the American Heart Association 2025 Yes

Showing 5 of 935 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages